TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Syngene International Ltd. ( (IN:SYNGENE) ) has shared an announcement.
Syngene International Ltd. has confirmed its expansion of biologics facilities to include new antibody-drug conjugate (ADC) bioconjugation capabilities, as reported in a news article. This strategic move aims to enhance their service offerings by providing end-to-end solutions for ADCs, from discovery to GMP manufacturing, thus accelerating development timelines. While this investment is part of the company’s ordinary business operations, it is not considered ‘material’ under current industry standards.
More about Syngene International Ltd.
Syngene International Ltd. operates in the biotechnology industry, offering integrated research, development, and manufacturing services. The company focuses on providing solutions for pharmaceutical, biotechnology, and agrochemical sectors, with a particular emphasis on biologics and bioconjugation capabilities.
Average Trading Volume: 40,591
Technical Sentiment Signal: Sell
Current Market Cap: 258.6B INR
See more insights into SYNGENE stock on TipRanks’ Stock Analysis page.